Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LNK 01001 (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Sponsors Lynk Pharmaceuticals

Most Recent Events

24 Oct 2023 Adverse event primary endpoint has been removed from the study, hence focus of this trial has been shifted to Tu only.
10 Oct 2023 Status changed from recruiting to completed.
09 Aug 2023 According to a Lynk Pharmaceuticals media release, company will continue to conduct validating the efficacy and safety of LNK01001 in Phase III clinical trials to benefit more patients.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com